secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0000950170-24-028666
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics enters new exec employment agreements with President and COO
--------------------------------------------------------------------------------

- President Eddie J. Sullivan gets annual base salary of $485,000; eligible for bonus up to 50% of salary.
- COO Christoph Bausch gets annual base salary of $425,000; eligible for bonus up to 40% of salary.
- Agreements effective Jan 1, 2024, replacing prior employment pacts; standard non-compete and non-solicit included.
- No changes to board or officer composition; both executives remain in same roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024028666/0000950170-24-028666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024028666/sabs-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-028666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer